Fas Ligand (TNF Superfamily, Member 6) (FASL) Antikörper

Antigen: Fas Ligand (TNF Superfamily, Member 6) (FASL)

Synonyme: FASL, CD178, CD95L, TNFSF6, APT1LG1, gld, Fas-L, Faslg, Tnfsf6, Fas-Ligand, FASLG, fasl, APT1, CD95, FAS1, APO-1, FASTM, ALPS1A, TNFRSF6, lpr, APO1, TNFR6, Tnfrsf6, AI196731, Fasl, CD95-L, Apt1Lg1, FAS, LOC574159, zgc:162027

Klonalität: Monoklonal (NOK-1)

Wirt: Maus

Reaktivität: Human

Applikation: Durchflusszytometrie (FACS), Immunpräzipitation (IP), Immunfluoreszenz (IF), Immunzytochemie (ICC)

Produktnummer: ABIN158284

Produktbeschreibung

Weitere Bezeichnung: Fas-L (CD178)

Immunogen: L5178Y mouse T lymphoma cells expressing recombinant human FasL

Format: Purified

Isotyp: IgG1, kappa chain

Klon: NOK-1

Beschreibung: CD178 is a 38-42 kD type II glycoprotein also known as Fas ligand and CD95L. CD178 belongs to the TNF superfamily and is expressed on activated T lymphocytes, NK cells, monocytes, and granulocytes. CD178 is also expressed on parenchymal cells of the retina and cornea, retinal pigment epithelial cells, and testis. The extracellular region of FasL can be cleaved by matrix metalloproteinases (MMPs) to give rise to a 26 kD soluble protein. CD178 binds to CD95, a member of the TNFR superfamily, to induce apoptosis. CD95/CD95L interactions play an important role in the maintenance of peripheral tolerance and survival. Distribution: Activated T cells, NK cells, testis, eye, neutrophils, Clara type II cells Function: Apoptosis, immune privilege Synonyms: Fas Ligand (FasL), CD95L, TNFSF6 Structure: TNF superfamily, type II glycoprotein, 38-42 kD, 26 kD soluble form

Synonyme: FASL, CD178, CD95L, TNFSF6, APT1LG1, gld, Fas-L, Faslg, Tnfsf6, Fas-Ligand, FASLG, fasl, APT1, CD95, FAS1, APO-1, FASTM, ALPS1A, TNFRSF6, lpr, APO1, TNFR6, Tnfrsf6, AI196731, Fasl, CD95-L, Apt1Lg1, FAS, LOC574159, zgc:162027

Anwendungen

Applikationshinweise: Additional reported applications (for the relevant formats) include: immunoprecipitation, immunofluorescence microscopy, immunocytochemistry, and blocking of Fas induced apoptosis. Fas Ligand is expressed at low density on activated cells. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (ABIN158288) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated antibody (ABIN158286) or biotinylated anti-mouse IgG second step (ABIN159908), followed by SAv-PE (ABIN159899)). In addition, applying matrix metalloproteinases (MMPS) inhibitor in the cell culture system will increase the FasL staining intensity. The LEAF(TM) purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm sterile-filtered) is recommended for functional assays (ABIN158290). Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is < 1.0 µg per 10 cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Reinigung: The antibody was purified by affinity chromatography.

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Lagerung: The antibody solution should be stored undiluted at 4°C.

Forschungsgebiet: CD Antigene, Apoptose/Nekrose, Virologie, Krebs

Beschränkungen: Nur für Forschungszwecke einsetzbar

Bilder

Human Fas Ligand transfected cells stained with purified NOK-1, followed by biotinylated anti-mouse IgG and Sav-PE

Publikationen

Publikationen: Kayagaki, Kawasaki, Ebata et al.: "Metalloproteinase-mediated release of human Fas ligand." in: The Journal of experimental medicine, Vol. 182, Issue 6, pp. 1777-83, 1996 (PubMed).

Bossi, Griffiths: "Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells." in: Nature medicine, Vol. 5, Issue 1, pp. 90-6, 1999 (PubMed).

Fujita, Chuganji, Yaginuma et al.: "Case report: acute encephalitis immediately prior to acute onset of hepatitis C virus infection." in: Journal of gastroenterology and hepatology, Vol. 14, Issue 11, pp. 1129-31, 2000 (PubMed).

Andreola, Rivoltini, Castelli et al.: "Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles." in: The Journal of experimental medicine, Vol. 195, Issue 10, pp. 1303-16, 2002 (PubMed).